Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial.

QUASAR Collaborative Group

doi:10.1016/S0140-6736(00)02214-5

Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial.

QUASAR Collaborative Group

Research output: Contribution to journal › Article › peer-review

255 Citations (Scopus)

Abstract

Standard adjuvant chemotherapy for colorectal cancer consists of fluorouracil with folinic acid or levamisole. The large QUASAR randomised trial aimed to investigate (in a two x two design) whether use of a higher dose of folinic acid or addition of levamisole to fluorouracil and folinic acid improved survival.

Original language	English
Pages (from-to)	1588-96
Number of pages	9
Journal	Lancet
Volume	355
Issue number	9215
DOIs	https://doi.org/10.1016/S0140-6736(00)02214-5
Publication status	Published - 6 May 2000

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Adjuvants, Immunologic
Antimetabolites, Antineoplastic
Chemotherapy, Adjuvant
Colonic Neoplasms
Drug Therapy, Combination
Fluorouracil
Humans
Leucovorin
Levamisole
Neoplasm Recurrence, Local
Radiotherapy, Adjuvant
Rectal Neoplasms
Survival Analysis

Access to Document

10.1016/S0140-6736(00)02214-5

Cite this

@article{1f71c1f0e11441ebb6914a8bbd3f2776,

title = "Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial.",

abstract = "Standard adjuvant chemotherapy for colorectal cancer consists of fluorouracil with folinic acid or levamisole. The large QUASAR randomised trial aimed to investigate (in a two x two design) whether use of a higher dose of folinic acid or addition of levamisole to fluorouracil and folinic acid improved survival.",

keywords = "Adjuvants, Immunologic, Antimetabolites, Antineoplastic, Chemotherapy, Adjuvant, Colonic Neoplasms, Drug Therapy, Combination, Fluorouracil, Humans, Leucovorin, Levamisole, Neoplasm Recurrence, Local, Radiotherapy, Adjuvant, Rectal Neoplasms, Survival Analysis",

author = "Steele, \{Robert J. C.\} and \{QUASAR Collaborative Group\}",

year = "2000",

month = may,

day = "6",

doi = "10.1016/S0140-6736(00)02214-5",

language = "English",

volume = "355",

pages = "1588--96",

journal = "Lancet",

issn = "0140-6736",

publisher = "Elsevier",

number = "9215",

}

TY - JOUR

T1 - Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer

T2 - a randomised trial.

AU - QUASAR Collaborative Group

A2 - Steele, Robert J. C.

PY - 2000/5/6

Y1 - 2000/5/6

N2 - Standard adjuvant chemotherapy for colorectal cancer consists of fluorouracil with folinic acid or levamisole. The large QUASAR randomised trial aimed to investigate (in a two x two design) whether use of a higher dose of folinic acid or addition of levamisole to fluorouracil and folinic acid improved survival.

AB - Standard adjuvant chemotherapy for colorectal cancer consists of fluorouracil with folinic acid or levamisole. The large QUASAR randomised trial aimed to investigate (in a two x two design) whether use of a higher dose of folinic acid or addition of levamisole to fluorouracil and folinic acid improved survival.

KW - Adjuvants, Immunologic

KW - Antimetabolites, Antineoplastic

KW - Chemotherapy, Adjuvant

KW - Colonic Neoplasms

KW - Drug Therapy, Combination

KW - Fluorouracil

KW - Humans

KW - Leucovorin

KW - Levamisole

KW - Neoplasm Recurrence, Local

KW - Radiotherapy, Adjuvant

KW - Rectal Neoplasms

KW - Survival Analysis

U2 - 10.1016/S0140-6736(00)02214-5

DO - 10.1016/S0140-6736(00)02214-5

M3 - Article

C2 - 10821362

SN - 0140-6736

VL - 355

SP - 1588

EP - 1596

JO - Lancet

JF - Lancet

IS - 9215

ER -

Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial.

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this